By discovering new uses of known drugs, reformulating and designing drug delivery modes best suited for each patient population, NeuroHealing believes it can bring needed products to the market. NeuroHealing currently has in development three drug candidates, all with preliminary evidence of clinical benefit: NH001 to accelerate the emergence of patients from a coma, NH004 to treat the social debilitating condition of sialorrhea (excessive salivation) and NH02D for the treatment of premature ejaculation.
Guided by a strong and experienced management team, NeuroHealing plans to become a leading pharmaceutical company addressing the needs of under-served patient populations.
.